Time‐to‐Event Analysis of Polatuzumab Vedotin‐Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens

Polatuzumab vedotin, an antibody‐drug conjugate containing monomethyl auristatin E, was associated with an incidence of grade ≥2 peripheral neuropathy (PN) of 55–72% in patients with indolent non‐Hodgkin lymphoma in a phase II study, when dosed 1.8–2.4 mg/kg every 3 weeks until progression or for a...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :CPT Pharmacometrics Syst Pharmacol
Главные авторы: Lu, D, Gillespie, WR, Girish, S, Agarwal, P, Li, C, Hirata, J, Chu, Y‐W, Kagedal, M, Leon, L, Maiya, V, Jin, JY
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2017
Предметы:
Original Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5488137/
https://ncbi.nlm.nih.gov/pubmed/28544534
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12192
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы